Eli Lilly and Company (NYSE:LLY) shares are in the spotlight Monday as the company presents new data at the Alzheimer’s Association International Conference in London. Wall Street weighed in on the stock last week.
- Eli Lilly stock is trading flat. What’s next for LLY stock?
The AAIC Presentation
Eli Lilly is presenting 16 abstracts at the 2026 Alzheimer’s Association International Conference, running July 12-15 in London, with significant new data expected on its Alzheimer’s treatment Kisunla. The presentations could help clarify Kisunla’s competitive standing in a market where diagnosis bottlenecks, required scans, and monitoring requirements remain key hurdles to broader adoption.
Kisunla at a Glance
Kisunla is an amyloid-targeting monoclonal antibody approved for people with mild cognitive impairment or mild dementia due to early symptomatic Alzheimer’s disease with confirmed amyloid pathology. It’s given as an intravenous infusion every four weeks and can cause serious side effects, including ARIA and infusion-related reactions. ApoE e4 homozygotes have a higher risk of ARIA, so testing for ApoE e4 status is recommended before treatment begins. Patients should discuss any safety concerns with their health care providers.
Analyst Consensus & Recent Actions
The stock carries a Buy rating with an average price target of $1293.73. Recent analyst moves include:
- B of A Securities: Buy (Raises Target to $1334.00) (July 10)
- Truist Securities: Buy (Raises Target to $1370.00) (July 8)
- Morgan Stanley: Overweight (Raises Target to $1347.00) (July 8)
Eli Lilly Shares Trade Flat
LLY Price Action: At the time of publication, Eli Lilly shares are edging 0.01% higher at $1,188.75, according to data from Benzinga Pro.
Image via Shutterstock
Recent Comments